Print Page   |   Sign In   |   Become a Member
Site Search
Experimental Hematology

ISEH Members

ISEH Members click here to access your free subscription to Experimental Hematology

If you forgot your login and password, please contact

Not an ISEH Member?

Subscribe Today! Or join ISEH and receive your FREE subscription.

Did you know?

Experimental Hematology has on average 25,000 articles download per month

The FAST TRACK option offers expedited reviews, on request, for articles that have been previously considered by other top-ranked journals




Lipocalin-2 Levels in Acute and Chronic Graft-versus-Host Disease following Allogeneic Haematopoietic Stem Cell TransplantationOpen in a New Window

Allogeneic haematopoietic stem cell transplantation (HSCT) is the only therapeutic option for patients with haematological diseases such as acute leukaemia [1,2]. However, it is still associated with substantial morbidity partly related to graft-versus-host disease (GVHD). GVHD occurs in around 50% of stem cell recipients thus remaining a major complication [3-5]. Severe GVHD is associated with reduced survival [6] and impaired quality of life of affected patients [7]. Chronic GVHD (cGVHD) is one of the main causes of non-relapse mortality (NRM) and prolonged immunodeficiency [3,4].


Intracellular cytarabine triphosphate in circulating blasts post-treatment predicts remission status in patients with acute myeloid leukemiaOpen in a New Window

Prediction of response to therapy and risk stratification is a major goal in the early treatment of acute myeloid leukemia (AML). Whilst complete remission (CR) rates have greatly improved in younger patients with AML, high relapse rates and poor disease-free survival still pose a significant challenge [1]. The backbone of AML therapy is cytarabine (ara-C), given at one of three dosing levels, depending on stage of disease (induction or relapse) and patient fitness (intensive or non-intensive therapy).


Chronic graft-versus-host disease and the risk of primary disease relapse: A meta-analysisOpen in a New Window

Primary disease relapse (PDR) and graft-versus-host disease (GVHD) have long been dreaded consequences of many malignant hematologic conditions. Active research is ongoing to further characterize and find effective methods to circumvent these complications.


Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1Open in a New Window

Acute leukemia patients often harbor genomic translocation events that give rise to oncogenic fusion proteins [1,2]. The t(10;11)(p13;q14) translocation is a recurrent, balanced translocation observed in human leukemia, which gives rise to the CALM-AF10 fusion protein [3,4]. Patients harboring the CALM-AF10 fusion have a particularly poor prognosis [5,6]. Standard chemotherapeutic strategies are often not very effective in treating patients with CALM-AF10 fusions. Hence, there is an urgent need to identify molecular pathways dysregulated in CALM-AF10-positive leukemias, which may lay the foundation for novel targeted therapies.


Human erythroblasts with c-Kit activating mutations have reduced cell culture costs and remain capable of terminal maturationOpen in a New Window

A major barrier to the in vitro production of red blood cells for transfusion therapy is the cost of culture components, with cytokines making up greater than half of the culture costs. Cell culture cytokines also represent a major expense for in vitro studies of human erythropoiesis. HUDEP-2 cells are an E6/E7 immortalized erythroblast line used for the in vitro study of human erythropoiesis. In contrast to other cell lines used to study human erythropoiesis, such as K562 cells, HUDEP-2 cells are capable of terminal maturation, including hemoglobin accumulation and chromatin condensation.


WITHDRAWN: Assessment of hematopoietic and neurologic pathophysiology of HCLS1-associated protein X-1 deficiency in a Hax1-knockout mouse modelOpen in a New Window

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.The full Elsevier Policy on Article Withdrawal can be found at


Association Management Software Powered by YourMembership  ::  Legal